NCT03867071View on ClinicalTrials.gov

Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Trauma
Interventions
OTHER

recombinant erythropoietin injection

Intravenous injection of 300 international units (IU) per kg (kg) of recombinant erythropoietin with a maximum of 20.000 IU, daily for a maximum of 10 days (D0 to D9).

OTHER

placebo injection

Intravenous injection 0,9% saline solution.

Trial Locations (1)

30029

Nimes university hospital, Nîmes

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER

NCT03867071 - Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients | Biotech Hunter | Biotech Hunter